Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xilio Therapeutics (XLO) Cash from Financing Activities (2024 - 2025)

Xilio Therapeutics' Cash from Financing Activities history spans 2 years, with the latest figure at -$285000.0 for Q3 2025.

  • For Q3 2025, Cash from Financing Activities fell 9400.0% year-over-year to -$285000.0; the TTM value through Sep 2025 reached $60.1 million, changed N/A, while the annual FY2024 figure was $29.2 million, 545.74% up from the prior year.
  • Cash from Financing Activities for Q3 2025 was -$285000.0 at Xilio Therapeutics, down from $47.4 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $47.4 million in Q2 2025 and bottomed at -$285000.0 in Q3 2025.